Bristol Myers Squibb Co

This management proposal requests a non-binding advisory 'say-on-pay' approval of the compensation disclosed for the company’s Named Executive Officers. Management is seeking shareholder endorsement of its executive compensation framework, which emphasizes a high proportion of performance-based and long-term equity incentives (approximately 80% of CEO target pay at risk and majority of NEO pay in PSUs and MSUs), metrics tied to Growth Portfolio Revenue and non-GAAP Operating Income, and governance mechanisms such as clawbacks and share ownership guidelines. The board and Compensation and Management Development Committee assert that the program aligns pay with company strategy and shareholder value, and note robust shareholder engagement and high prior-year support. The proposal is routine and advisory; a favorable vote signals support but does not bind the Board. The argument for support is that the program links pay to near-term and long-term performance, while the counterargument by dissenting shareholders may be concerns over pay levels or metric design; management emphasizes rigorous governance, market benchmarking, and retention/attraction of talent to justify levels.

Management is requesting shareholder approval of the 2026 Plan, an omnibus equity-and-cash incentive plan that would reserve 85 million shares (plus certain carryovers) for future awards. The proposal asks shareholders to replace the 2021 Plan with the 2026 Plan to ensure continuing capacity to grant ISOs, SARs, RSUs, PSUs, MSUs, cash performance awards and other equity-linked incentives. The board justifies the plan as necessary to attract and retain talent globally, align pay with shareholder interests, and support long-term value creation; the committee highlights governance features including per-person annual limits, non-repricing without shareholder approval, limits on non-employee director compensation, and anti-hedging/pledging policies. Notable contextual points: the plan would represent ~5.9% of outstanding shares as of March 12, 2026 and management expects the share reserve to support grant needs for approximately six years based on recent burn rates. Proxy-language discloses that the Committee may adjust awards in corporate transactions and imposes limits to comply with tax rules (Section 409A and 162(m)), and contains change-in-control provisions. Risk considerations for shareholders include potential dilution, the size of the reserve relative to peers and historical burn rates, and the flexibility for adjustments and substitute awards in M&A which may increase usage; mitigants include strict annual per-person limits and shareholder approval required for repricing.

This shareholder proposal, put forward by John Chevedden, asks the Board to adopt an enduring policy requiring the Board Chair be an independent director and for the roles of Chair and CEO to be held by separate individuals. The proponent argues separation will enhance governance, impartial oversight, shareholder protections, and management accountability — citing product trial failures, stock underperformance, high debt, and regulatory headwinds as reasons. Management and the Board oppose the proposal, arguing flexibility to choose the optimal leadership structure is critical, that the Lead Independent Director performs independent oversight duties similar to those of an independent chair, and that previous similar proposals have failed to secure majority support. For governance analysts, key considerations include the tradeoff between unified leadership and independent oversight, the specific authority and effectiveness of the company’s Lead Independent Director and governance practices, recent board refreshment and committee independence, historical shareholder voting on similar proposals, and whether company-specific performance issues warrant a structural change or improved accountability mechanisms. The board’s opposition highlights fiduciary discretion under Delaware law, potential rigidity of an enduring policy, and the company’s tailored governance mitigants; proponent’s case emphasizes accountability amid multiple clinical setbacks and strategic challenges. The contest centers on whether process flexibility or a prescriptive independence mandate is more likely to serve long-term shareholder value.